Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
April 15, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Melatonin is generally safe for short-term use and unlikely to cause dependence or reduced effectiveness over time — unlike many prescription sleep aids
  • The most common side effects are headache, dizziness, nausea, and daytime drowsiness; less common effects include vivid dreams, mood swings, stomach cramps, and a raised risk of falls
  • Melatonin interacts with a significant list of medications including blood thinners, anticonvulsants, birth control, diabetes drugs, immunosuppressants, and high blood pressure medicine
  • Over-the-counter melatonin supplements vary widely in actual melatonin content — consulting a healthcare provider before use is recommended, especially for anyone on other medications

What Happened?

Melatonin is a naturally occurring hormone that signals the body to prepare for sleep, with blood levels peaking at night. Supplemental melatonin has become one of the most widely used sleep aids globally, available over the counter in most markets. According to Mayo Clinic’s guidance, research supports its usefulness for specific conditions — delayed sleep phase disorder, insomnia, and jet lag — but evidence for broader or long-term use remains limited. Critically, OTC melatonin supplements vary widely in the actual dose delivered, making self-selection unreliable without professional guidance. The most common side effects — headache, dizziness, nausea, and daytime drowsiness — are manageable for most users, but a longer list of less common effects and drug interactions can make it inappropriate for many people without medical review.

Why It Matters?

Melatonin’s reputation as a “natural” and therefore automatically safe supplement is widely overstated. The drug interaction list is substantial: melatonin can interfere with blood thinners, seizure medications, birth control pills, high blood pressure drugs, diabetes medications, immunosuppressants, and any medication processed by the liver — a category that covers a large portion of commonly prescribed drugs. Less recognized side effects including urinary incontinence, raised seizure risk, confusion, and increased fall risk are especially relevant for older adults, who are both the highest users of sleep aids and the most vulnerable to these adverse outcomes. The long-term safety profile also remains inadequately studied, making chronic use a less well-understood risk than most consumers realize.

What’s Next?

Mayo Clinic recommends against using melatonin as a first-line or standalone solution for sleep problems. The evidence-backed approach combines melatonin — when appropriate — with lifestyle interventions: consistent sleep hygiene, regular exercise, good nutrition, stress reduction practices, and social connection. For anyone already on prescription medications, a conversation with a healthcare provider before starting melatonin is not optional advice — it is a genuine clinical necessity given the breadth of documented drug interactions.

Source: Mayo Clinic

Previous Post

A Major European Bank Just Brought Its Stablecoin to Millions of Crypto Wallets — But Can It Compete?

Next Post

China Beat Q1 Growth Targets With 5% GDP — But the Iran War Is Already Eroding the Foundation

Recommended For You

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
4 days ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
1 week ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
2 weeks ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
2 weeks ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
3 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
4 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
4 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
4 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
1 month ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more
Next Post
China’s Bold Economic Moves: What You Need to Know Now

China Beat Q1 Growth Targets With 5% GDP — But the Iran War Is Already Eroding the Foundation

OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

The Man Who Attacked OpenAI's HQ Had Talked About 'Luigi-ing Tech CEOs' Months Before

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China’s Housing Market: Eased Policies Show Promise Amid Economic Struggles

Home Buyers Gain Leverage as Discounts Hit Multi-Year Highs

February 9, 2026
person in white shirt and blue jeans walking inside GAP store

Gap Expects Stronger Headwinds From Tariffs — Investor Summary

August 29, 2025
Robinhood Expands Beyond U.S. with $200M Bitstamp Acquisition

Robinhood Expands Beyond U.S. with $200M Bitstamp Acquisition

June 6, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018